Jessica L. Mega, MD, MPH, is the Chief Medical Officer at Verily Life Sciences. As a faculty member at Harvard Medical School (on leave), a senior investigator with the TIMI Study Group, and a cardiologist at Brigham and Women’s Hospital, she led large, international, randomized trials evaluating novel cardiovascular therapies. She also directed the TIMI Study Group’s Genetics Program. Her research findings have been published in the New England Journal of Medicine, Lancet, JAMA, and elsewhere. Dr. Mega is a graduate of Stanford University, Yale University School of Medicine and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes awards, and was named one of the Most Influential Women in Bay Area Business 2019 by the San Francisco Business Times. She is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).
New technologies let you measure thousands of health parameters that can be collected in a proactive healthcare system. Focusing on comprehensive health data early on can keep individuals healthy. To achieve this we need to establish the baseline for each individual which is a prerequisite for precision health. This session will focus on making precision medicine mainstream via managing and utilizing big data and genome sequence information.